Link Details
- Metabolite
- HMDB0000562 (Creatinine)
- DrugBank ID
- DB01609
- Drug Name
- Deferasirox
- Effect
- Increase
- Biospecimen
- Blood
- P-value
- Not Available
- Beta Estimator
- Not Available
- Percent Change
- Not Available
- Pearson Correlation Coefficient
- Not Available
- Comments
- Not Available
- Chang HH, Lu MY, Liao YM, Lin PC, Yang YL, Lin DT, Chiou SS, Jou ST, Lin KH, Chang TT: Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent beta-thalassemia. Pediatr Blood Cancer. 2011 Mar;56(3):420-4. doi: 10.1002/pbc.22826. [PubMed:21072825 ]
- Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T: A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007 Feb;136(3):501-8. [PubMed:17233848 ]
- Rheault MN, Bechtel H, Neglia JP, Kashtan CE: Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer. 2011 Apr;56(4):674-6. doi: 10.1002/pbc.22711. Epub 2010 Dec 6. [PubMed:21298760 ]
- Chaudhary P, Pullarkat V: Deferasirox: appraisal of safety and efficacy in long-term therapy. J Blood Med. 2013 Aug 5;4:101-10. doi: 10.2147/JBM.S35478. eCollection 2013. [PubMed:23966805 ]